Merck files marketing application for COVID-19 pill in Japan

2021-12-03 08:32:31

Asian Tech Press (Dec 3) -- U.S. drug company Merck Sharp & Dohme Corp. (MSD) has reportedly filed an application to market its COVID-19 pill molnupiravir in Japan.

A Japanese subsidiary of Merck has applied for approval in Japan to manufacture and market molnupiravir, an antiviral drug that inhibits coronavirus replication, Nikkei reported Friday.

If approved, it would be the first COVID-19 drug in Japan to target patients with mild or intermediate symptoms.

The Japanese government has decided to spend nearly $1.2 billion for 1.6 million courses of Merck's COVID-19 pill.

COVID-19 pill Merck Japan

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03